Adjuvant therapeutic strategies for resectable pancreatic adenocarcinoma

Of all patients diagnosed with pancreatic adenocarcinoma, only 15–20% present with resectable disease. Despite curative-intent resection, the prognosis remains poor with the majority of patients recurring, prompting the need for adjuvant therapy. Historical data support the use of adjuvant 5-fluorou...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Ann Pancreat Cancer
Main Authors: Yegya-Raman, Nikhil, Shah, Mihir M., Grandhi, Miral S., Poplin, Elizabeth, August, David A., Kennedy, Timothy J., Malhotra, Usha, Spencer, Kristen R., Carpizo, Darren R., Jabbour, Salma K.
Format: Artigo
Jezik:Inglês
Izdano: 2018
Teme:
Article
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC6345263/
https://ncbi.nlm.nih.gov/pubmed/30687847
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.21037/apc.2018.07.05
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki